QQ客服 官方微博 反馈留言

浏览/检索结果: 共10条，第1-10条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells 期刊论文 THORACIC CANCER, 2021, 页码: 9 作者:  Zhang, Mi;  Quan, Haitian;  Fu, Li;  Li, Yun;  Fu, Haoyu 收藏  |  浏览/下载：18/0  |  提交时间：2021/05/24 EGFR‐  mutant non‐  small cell lung cancer  famitinib  HS‐  10296  multi‐  targeted tyrosine kinase inhibitor  third‐  generation EGFR inhibitor   Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial 期刊论文 CHINESE JOURNAL OF CANCER, 2017, 卷号: 36 作者:  Xu, Rui-Hua;  Shen, Lin;  Wang, Ke-Ming;  Wu, Gang;  Shi, Chun-Mei 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05 Colorectal cancer  Famitinib  Efficacy  Safety   Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double‑blinded, placebo‑controlled, phase II clinical trial 期刊论文 2017, 卷号: 36, 期号: 12, 页码: 677-685 作者:  Xu Ruihua;  Shen Lin;  Wang Keming;  Wu Gang;  Shi Chunmei 收藏  |  浏览/下载：7/0  |  提交时间：2020/01/04 Colorectal cancer  Famitinib  Efficacy  Safety   Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial 期刊论文 2017, 卷号: 36, 期号: 1, 页码: 97 作者:  Xu, Rui-Hua;  Shen, Lin;  Wang, Ke-Ming;  Wu, Gang;  Shi, Chun-Mei 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/04 Colorectal cancer  Famitinib  Efficacy  Safety   Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer 期刊论文 CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 卷号: 74, 期号: 2 作者:  Cao, Jun;  Zhang, Jian;  Wang, Zhonghua;  Wang, Biyun;  Lv, Fangfang 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/19 Breast cancer  Famitinib  Hypothyroidism  Tyrosine kinase  VEGF  VEGFR-2   Predicting pharmacokinetics of anti-cancer drug, famitinib in human using physiologically based pharmacokinetic model 期刊论文 Acta Pharmaceutica Sinica, 2014, 卷号: 49, 期号: 12, 页码: 1684-1688 作者:  Yu Mingming;  Gao Zhiwei;  Chen Xiaoyan;  Zhong Dafang 收藏  |  浏览/下载：34/0  |  提交时间：2019/01/08 famitinib  physiologically based pharmacokinetic model  species extrapolation  tyrosine kinase inhibitor   Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib 期刊论文 CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 卷号: 72, 期号: 5, 页码: 1043-1053 作者:  Zhou, Aiping;  Zhang, Wen;  Chang, Chunxiao;  Chen, Xiaoyan;  Zhong, Dafang 收藏  |  浏览/下载：40/0  |  提交时间：2019/01/08 Famitinib  Phase I trial  Safety  Pharmacokinetics  Antitumor activity   Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients 期刊论文 BRITISH JOURNAL OF PHARMACOLOGY, 2013, 卷号: 168, 期号: 7, 页码: 1687-1706 作者:  Xie, Cen;  Zhou, Jialan;  Guo, Zitao;  Diao, Xingxing;  Gao, Zhiwei 收藏  |  浏览/下载：47/0  |  提交时间：2019/01/08 famitinib  metabolism  bioactivation  quinone-imine  hepatotoxicity   Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib 期刊论文 2013, 卷号: 72, 期号: 5, 页码: 1043-1053 作者:  Zhou, Aiping;  Zhang, Wen;  Chang, Chunxiao;  Chen, Xiaoyan;  Zhong, Dafang 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/13 Famitinib  Phase I trial  Safety  Pharmacokinetics  Antitumor activity   Famitinib in metastatic renal cell carcinoma: a single center study 期刊论文 2013, 卷号: 126, 期号: 22, 页码: 4277-4281 作者:  Zhang Wen;  Zhou Ai-ping;  Qin Qiong;  Chang Chun-xiao;  Jiang Hao-yuan 收藏  |  浏览/下载：1/0  |  提交时间：2020/01/13 famitinib  metastatic renal cell carcinoma  efficacy  adverse reaction